KHK2455 has recently entered Phase 1 clinical trials for a host of cancer entities in combination therapy with the anti-PD-L1 monoclonal antibody (mAb) Avelumab in advanced bladder cancer (NCT03915405) and in combination with the anti-CCR4 mAb Mogamulizumab for locally advanced or metastatic solid tumours (NCT02867007).150 The clinical trials for KHK2455 have either not started or just started recruiting patients, therefore results are still awaited. Here, CD274 is linked to cancer.